Specific Modification with TPGS and Drug Loading of Cyclodextrin Polyrotaxanes and the Enhanced Antitumor Activity Study in Vitro and in Vivo
Source abstract
Abstract
A kind of specific cyclodextrin polyrotaxanes (PRs) drug delivery system was developed for an effective drug delivery and enhancing antitumor effect. In this work, we prepared the PR by using α-CD derivatives and dicarboxyl-PEG (Mn = 4200) self-assembling and end-capping with β-CD derivatives. Then, we chose d-a-Tocopheryl polyethylene glycol 1000 succinate (TPGS) with an antitumor effect to modify the PR. The modified PRs have a certain anticancer effect and can assist the anticancer drug to treat cancer. The 10-hydroxycamptothecin (HCPT) was combined to the specific PRs by covalent bonds to prepare drug-loaded specificity PRs (PR-TPGS-HCPT). The enhanced antitumor activities of PR-TPGS-HCPT were studied by in vitro and in vivo experiments, and the experiment results proved that the TPGS could effectively assist the drug to treat cancer and prolong the lifetime of the tumor-bearing mice. Therefore, this research provides a promising drug-loaded material for the cancer treatment and the specific water-soluble PRs will have potential applications in the biomedical field.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Supramolecular Chemistry and Complexes · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Public Health, Zhengzhou University, Zhengzhou 450001, People’s Republic of China
Funding
National Natural Science Foundation of China · Henan University · Higher Education Institutions in Henan Province · School of Medicine, Henan University
References (34)
Show source-provided references
1. 10.1021/ar500109h10.1021/ar500109h ↗
2. 10.1039/c4tb01821d10.1039/c4tb01821d ↗
3. 10.1166/jbn.2019.279910.1166/jbn.2019.2799 ↗
4. 10.1038/356325a010.1038/356325a0 ↗
5. 10.1039/c8bm01020j10.1039/c8bm01020j ↗
6. 10.1039/c8py00333e10.1039/c8py00333e ↗
7. 10.1016/j.colsurfb.2018.02.03210.1016/j.colsurfb.2018.02.032 ↗
8. 10.1016/j.biomaterials.2015.11.03210.1016/j.biomaterials.2015.11.032 ↗
9. 10.1016/j.jconrel.2012.07.01310.1016/j.jconrel.2012.07.013 ↗
10. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
11. 10.1021/acsami.5b0101610.1021/acsami.5b01016 ↗
12. 10.1080/14686996.2016.120094810.1080/14686996.2016.1200948 ↗
13. 10.1021/acs.macromol.6b0149310.1021/acs.macromol.6b01493 ↗
14. 10.1002/anie.20130139710.1002/anie.201301397 ↗
15. 10.3762/bjoc.12.28710.3762/bjoc.12.287 ↗
16. 10.1021/acs.bioconjchem.8b0052510.1021/acs.bioconjchem.8b00525 ↗
17. 10.1039/c5tb00627a10.1039/c5tb00627a ↗
18. 10.1021/acsbiomaterials.7b0046410.1021/acsbiomaterials.7b00464 ↗
19. 10.1016/j.ejps.2013.02.00610.1016/j.ejps.2013.02.006 ↗
20. 10.1016/j.colsurfb.2018.07.06010.1016/j.colsurfb.2018.07.060 ↗
21. 10.7150/thno.2271110.7150/thno.22711 ↗
22. 10.1016/j.jconrel.2018.03.00710.1016/j.jconrel.2018.03.007 ↗
23. 10.1002/bmc.345210.1002/bmc.3452 ↗
24. 10.1016/j.snb.2011.04.03510.1016/j.snb.2011.04.035 ↗
25. 10.1016/j.ijpharm.2013.10.00510.1016/j.ijpharm.2013.10.005 ↗
26. 10.1016/j.nano.2011.02.00610.1016/j.nano.2011.02.006 ↗
27. 10.1248/bpb.b13-0086310.1248/bpb.b13-00863 ↗
28. 10.1016/j.carbpol.2010.08.08010.1016/j.carbpol.2010.08.080 ↗
29. 10.1016/j.tet.2006.09.08910.1016/j.tet.2006.09.089 ↗
30. 10.1039/c1an15570a10.1039/c1an15570a ↗
31. 10.3762/bjoc.12.28710.3762/bjoc.12.287 ↗
32. 10.1021/ma050290+10.1021/ma050290+ ↗
33. 10.1016/j.biomaterials.2013.04.05210.1016/j.biomaterials.2013.04.052 ↗
34. 10.1021/nn900568610.1021/nn9005686 ↗